A simplified, sensitive immunohistochemical detection system employing signal amplification based on fluorescyl-tyramide/antifluorescein antibody reaction: Its application to pathologic testing and research

Applied Immunohistochemistry and Molecular Morphology

Volumn 16, Issue 1, 2008, Pages 87-93

  Hatanaka, Yutaka ^a   Imaoka, Yuki ^a   Torisu, Kae ^a   Kamihara, Yuki ^a   Hashizume, Kaoru ^a   Ichimura, Koichi ^b   Yoshino, Tadashi ^b   Tani, Yoichi ^a  

^a Dako Japan Inc   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Fluorescyl tyramide; Tyramide signal amplification

Indexed keywords

BIOLOGICAL MARKER; CHROMOGENIC SUBSTRATE; CYCLIN D1; FLUORESCEIN ANTIBODY; FLUORESCEIN DERIVATIVE; ISOPROPAMIDE IODIDE; PARAFFIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIGEN ANTIBODY REACTION; ARTICLE; B CELL LYMPHOMA; CATALYZED SIGNAL AMPLIFICATION; CELL DIFFERENTIATION; DIAGNOSTIC ACCURACY; DISEASE MARKER; HUMAN; HUMAN TISSUE; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL DETECTION; STAINING;

ANIMALS; ANTIBODIES; ANTIGENS, NEOPLASM; BIOTIN; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; NEOPLASMS; PARAFFIN EMBEDDING; SENSITIVITY AND SPECIFICITY; TYRAMINE;

EID: 37549002838     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31802ca9ea     Document Type: Article

References (23)

1. Bobrow MN, Harris TD, Shaughnessy KJ, et al. Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J Immunol Methods. 1989;125:279-285.
2. Bobrow MN, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification. II. Application to membrane immunoassays. J Immunol Methods. 1991;137:103-112.
3. Adams JC. Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. J Histochem Cytochem. 1992;40:1457-1463.
4. Merz H, Malisius R, Mannweiler S, et al. ImmunoMax. A maximized immunohistochemical method for the retrieval and enhancement of hidden antigens. Lab Invest. 1995;73:149-156.
5. Kerstens HM, Poddighe PJ, Hanselaar AG. A novel in situ hybridization signal amplification method based on the deposition of biotinylated tyramine. J Histochem Cytochem. 1995;43:347-352.
6. Macechko PT, Krueger L, Hirsch B, et al. Comparison of immunologic amplification vs enzymatic deposition of fluorochrome-conjugated tyramide as detection systems for FISH. J Histochem Cytochem. 1997;45:359-363.
7. van Gijlswijk RP, Zijlmans HJ, Wiegant J, et al. Fluorochrome-labeled tyramides: use in immunocytochemistry and fluorescence in situ hybridization. J Histochem Cytochem. 1997;45:375-382.
8. Mayer G, Bendayan M. Biotinyl-tyramide: a novel approach for electron microscopic immunocytochemistry. J Histochem Cytochem. 1997;45:1449-1454.
9. Gross AJ, Sizer IW. The oxidation of tyramine, tyrosine, and related compounds by peroxidase. J Biol Chem. 1959;234:1611-1614.
10. von Wasielewski R, Mengel M, Gignac S, et al. Tyramine amplification technique in routine immunohistochemistry. J Histochem Cytochem. 1997;45:1455-1459.
11. Hashizume K, Hatanaka Y, Kamihara Y, et al. Automated immunohistochemical staining of formalin-fixed and paraffin-embedded tissues using a catalyzed signal amplification method. Appl Immunohistochem Mol Morphol. 2001;9:54-60.
12. Hasui K, Takatsuka T, Sakamoto R, et al. Improvement of supersensitive immunohistochemistry with an autostainer: a simplified catalysed signal amplification system. Histochem J. 2002;34:215-222.
13. Hasui K, Murata F. A new simplified catalyzed signal amplification system for minimizing non-specific staining in tissues with supersensitive immunohistochemistry. Arch Histol Cytol. 2005;68:1-17.
14. Chan JK, Miller KD, Munson P, et al. Immunostaining for cyclin D1 and the diagnosis of mantle cell lymphoma: is there a reliable method? Histopathology. 1999;34:266-270.
15. Coelho Siqueira SA, Ferreira Alves VA, Beitler B, et al. Contribution of immunohistochemistry to small B-cell lymphoma classification. Appl Immunohistochem Mol Morphol. 2006;14:1-6.
16. Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol. 2002;29:231-245.
17. Miettinen M, El-Rifai W, H L Sobin L, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002;33:478-483.
18. Cappuzzo F, Gregorc V, Rossi E, et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol. 2003;21:2658-2663.
19. Kanematsu T, Yano S, Uehara H, et al. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res. 2003;13:289-298.
20. Thor AD, Liu S, Edgerton S, et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol. 2000;18:3230-3239.
21. DiGiovanna MP, Chu P, Davison TL, et al. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Res. 2002;62:6667-6673.
22. Park JW, Kerbel RS, Kelloff GJ, et al. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res. 2004;10:3885-3896.
23. Okada N, Sasaki A, Niwa M, et al. Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector. Cancer Gene Ther. 2006;13:393-405.